Quizartinib Standard Administration and Dosage Guidelines

The treatment plan of Quizartinib is divided into three stages: induction, consolidation and maintenance, which must be strictly implemented under the guidance of a doctor. The drug is taken orally once a day, with or without food, but it should be taken at the same time every day to maintain stable blood concentration.

In the induction phase (usually 7+3 regimen combined treatment), it is recommended to take 35.4 mg orally once a day starting from the 8th day for 14 consecutive days (day 8 to 21), which is a 28-day cycle. In the consolidation phase, the same dose (35.4 mg) is taken orally from day 6 and lasts for 14 days (day 6 to day 19) to further eliminate residual leukemia cells. After completing the consolidation treatment, enter the maintenance phase of treatment. If the patient's QTcF value is ≤450ms, the patient can take 26.5 mg daily from day 1 to day 14 of cycle 1, and the dose can be increased to 53 mg once daily from day 15 onwards. If QTcF>500ms during treatment, the dose should be reduced or medication should be suspended. The entire maintenance treatment phase can be continued for up to 36 cycles to delay disease recurrence.

For patients scheduled to undergo hematopoietic stem cell transplantation (HSCT), quizartinib needs to be discontinued at least 7 days before the start of the transplant conditioning regimen to avoid drug accumulation or the risk of QT prolongation. Usually, patients can receive up to 2 induction cycles and 4 consolidation cycles, and the specific treatment course needs to be adjusted based on myelological response and tolerance.

During the treatment process, doctors need to regularly monitor the patient's electrocardiogram, liver and kidney function, and blood cell count to evaluate the safety of the drug. Quizartinib's precise inhibition of the FLT3 signaling pathway makes the treatment more targeted and has milder side effects than traditional chemotherapy, but it may still cause reactions such as mild gastrointestinal discomfort, QT interval prolongation, or neutropenia.

In general, the standard usage of quizartinib emphasizes the treatment concept of "staged, continuous and precise monitoring", which is a typical representative of modern AML targeted therapy.

Reference materials:https://go.drugbank.com/drugs/DB12874